|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM194934683 |
| 003 |
DE-627 |
| 005 |
20231223201716.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.01.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0650.xml
|
| 035 |
|
|
|a (DE-627)NLM194934683
|
| 035 |
|
|
|a (NLM)20138586
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Paquin Proulx, Dominic
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.06.2010
|
| 500 |
|
|
|a Date Revised 11.05.2010
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Previous work from our laboratory revealed that IVIg interacted with intracellular proteins involved in antigen presentation in B cells, suggesting that IVIg might interfere with the process of antigen presentation in these cells. In the present work, we used an in vitro assay with ovalbumin as model antigen and showed that IVIg inhibited both BCR-dependent and BCR-independent antigen presentation. The inhibition could not be explained by a modulation of expression of MHC II molecules expressed on B cells and was shown to occur in an FcgammaRIIb-independent manner, suggesting that the events responsible for the inhibitory effect occur at the intracellular level. This was supported by the observation of a direct correlation between the level of spontaneous internalization of two different proteins (IVIg and HSA) and their inhibitory potential. The inhibition of B cell-mediated antigen presentation reported here may help explain some of the anti-inflammatory effects of IVIg observed in treated patients, such as a decrease in autoantibody production
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, B-Cell
|2 NLM
|
| 700 |
1 |
|
|a Aubin, Eric
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lemieux, Réal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bazin, Renée
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 135(2010), 3 vom: 08. Juni, Seite 422-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:135
|g year:2010
|g number:3
|g day:08
|g month:06
|g pages:422-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.01.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 135
|j 2010
|e 3
|b 08
|c 06
|h 422-9
|